Sarah O'Brien - Jan 10, 2023 Form 4 Insider Report for Provention Bio, Inc. (PRVB)

Role
Chief People Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Stock symbol
PRVB
Transactions as of
Jan 10, 2023
Transactions value $
$0
Form type
4
Date filed
1/11/2023, 08:13 PM
Previous filing
Sep 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +8K +8% $0.00 108K Jan 10, 2023 Common Stock, par value $0.0001 8K $5.35 Direct F1, F2
transaction PRVB Stock Option (right to buy) Award $0 +100K $0.00 100K Jan 10, 2023 Common Stock, par value $0.0001 100K $8.93 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 4 filed on September 19, 2022, on September 15, 2022, the Reporting Person was granted a stock option for 200,000 shares of Common Stock, 100,000 of which option shares vest in four equal annual installments commencing on September 15, 2023 and 100,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 8,000 of the 100,000 performance options shares on January 10, 2023 upon the satisfaction of certain performance milestones.
F2 The stock options were granted pursuant to the Issuer's 2020 Inducement Plan, as amended.
F3 The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027).
F4 The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.